Specify a stock or a cryptocurrency in the search bar to get a summary
Galecto Inc
GLTOGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark. Address: Ole Maaloes Vej 3, Copenhagen, Denmark, 2200
Analytics
WallStreet Target Price
225 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures GLTO
Dividend Analytics GLTO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History GLTO
Stock Valuation GLTO
Financials GLTO
Results | 2019 | Dynamics |